Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching hospital.

ABSTRACT:

Background and aim

Comirnaty® was the first COVID-19 vaccine available for the vaccination campaign of healthcare workers in Italy. With the aim of assessing vaccine safety, we conducted a cross-sectional survey administrating a voluntary-based questionnaire on adverse events following immunisation (AEFIs) in San Raffaele Hospital, Milano, Italy.

Methods

From 4th January 2021 to 27th April 2021, we collected 2,659 questionnaires (response rate: 24,5%). We analyzed data, reporting AEFIs by gender, age, self-reported severity, type, time of insurgence and duration, and estimating relative-risk ratios (RRR) and corresponding 95% confidence intervals (CI).

Results

The most reported symptoms were injection site pain, fatigue, headache, myalgia, chills, fever, and arthralgi

SUBMITTER: Vigezzi GP 

PROVIDER: S-EPMC8851005 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature